Back to results
US 8,569,543 B2Granted
CCR9 inhibitors and methods of use thereof
AssigneeMillennium Pharmaceuticals, Inc.
InventorsPaul E. Fleming, Geraldine C. B. Harriman, Zhan Shi, B. Shaowu Chen
Life of this patent
Estimating the term…
Abstract
The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.
Claims7
A compound having the following structural formula:
- or a pharmaceutically acceptable salt thereof, wherein:
- Y is S(O), or S(O)2;
- R8 is halo, nitro, alkylcarbonyl, or trihaloalkyl;
- Ar1 is substituted or unsubstituted phenyl;
- and
- Ar2 is a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group.
3 more elements
Dependencies are inferred from the claim text.